Investors Buy Large Volume of Call Options on Summit Therapeutics (NASDAQ:SMMT)

Summit Therapeutics PLC (NASDAQ:SMMT) saw unusually large options trading on Friday. Investors purchased 20,849 call options on the company. This represents an increase of approximately 147% compared to the average volume of 8,434 call options.

Insider Transactions at Summit Therapeutics

In other news, CEO Robert W. Duggan bought 3,810,000 shares of the stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average cost of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the acquisition, the chief executive officer owned 573,883,879 shares in the company, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Mahkam Zanganeh purchased 3,810,000 shares of the company’s stock in a transaction on Friday, June 12th. The shares were purchased at an average cost of $13.12 per share, for a total transaction of $49,987,200.00. Following the completion of the transaction, the chief executive officer directly owned 573,883,879 shares of the company’s stock, valued at approximately $7,529,356,492.48. This represents a 0.67% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have purchased a total of 7,870,000 shares of company stock worth $103,616,900 in the last 90 days. Corporate insiders own 83.50% of the company’s stock.

Hedge Funds Weigh In On Summit Therapeutics

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC grew its holdings in shares of Summit Therapeutics by 5.0% during the 1st quarter. AQR Capital Management LLC now owns 65,623 shares of the company’s stock valued at $1,266,000 after purchasing an additional 3,134 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Summit Therapeutics by 1.1% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 65,411 shares of the company’s stock worth $1,273,000 after purchasing an additional 694 shares during the last quarter. Creative Planning grew its stake in shares of Summit Therapeutics by 6.7% in the second quarter. Creative Planning now owns 21,390 shares of the company’s stock worth $455,000 after purchasing an additional 1,336 shares during the last quarter. Legal & General Group Plc increased its holdings in Summit Therapeutics by 33.8% in the second quarter. Legal & General Group Plc now owns 26,367 shares of the company’s stock valued at $561,000 after purchasing an additional 6,662 shares during the period. Finally, Quantbot Technologies LP acquired a new stake in Summit Therapeutics in the second quarter valued at $132,000. Institutional investors and hedge funds own 4.61% of the company’s stock.

Summit Therapeutics Stock Performance

SMMT stock opened at $13.66 on Friday. Summit Therapeutics has a 52 week low of $12.55 and a 52 week high of $30.98. The company has a market capitalization of $10.60 billion, a PE ratio of -12.20 and a beta of -1.26. The company’s 50-day simple moving average is $15.03 and its 200 day simple moving average is $16.68.

Summit Therapeutics (NASDAQ:SMMT) last issued its quarterly earnings data on Thursday, July 23rd. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.27) by ($0.01). On average, analysts forecast that Summit Therapeutics will post -1.18 EPS for the current year.

Analyst Ratings Changes

Several research firms have recently weighed in on SMMT. Weiss Ratings restated a “sell (d-)” rating on shares of Summit Therapeutics in a research note on Friday, July 17th. Sanford C. Bernstein assumed coverage on Summit Therapeutics in a report on Thursday, May 21st. They set an “underperform” rating and a $7.70 price target for the company. HC Wainwright reiterated a “neutral” rating on shares of Summit Therapeutics in a research note on Thursday. Stifel Nicolaus cut their target price on shares of Summit Therapeutics from $45.00 to $38.00 and set a “buy” rating for the company in a research note on Friday. Finally, Wall Street Zen cut Summit Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $26.15.

Key Stories Impacting Summit Therapeutics

Here are the key news stories impacting Summit Therapeutics this week:

• Positive Sentiment: Summit reported updated Phase III survival data for its HARMONi lung cancer study and said its lead drug ivonescimab continues to advance, including new development collaborations that broaden its pipeline optionality. Article Title
• Positive Sentiment: Unusually heavy options activity, with call volume far above normal, suggests traders are positioning for a possible rebound or additional catalyst-driven upside.
• Neutral Sentiment: The company’s Q2 earnings call and presentation focused on clinical and operational progress, keeping attention on future data readouts rather than near-term revenue generation. Article Title
• Neutral Sentiment: HC Wainwright reaffirmed a neutral rating, reinforcing that analysts remain cautious while waiting for clearer evidence that ivonescimab can deliver commercially meaningful results. Article Title
• Negative Sentiment: Summit posted a wider-than-expected Q2 loss with no revenue, highlighting continued cash burn and reliance on future clinical success to justify its valuation. Article Title
• Negative Sentiment: An article noted that analyst expectations were being tempered after the initial lung cancer survival data, which may be pressuring sentiment and contributing to the stock’s recent weakness. Article Title

Summit Therapeutics Company Profile

Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies.

Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S.